Recommended dose: 5 mcg/kg daily SC bolus or short IV infusion, given over 30 min. Should be administered no earlier than 24 hr after the administration of cytotoxic chemotherapy & not be administered in the period 24 hr before the administration of chemotherapy.
View Filgia overdosage for action to be taken in the event of an overdose.
Contraindications
Unknown hypersensitivity to E. coli-derived proteins, filgastrim. Myeloid malignancy. Not to be used to increase the dose of cytotoxic chemotherapy beyond dosage regimens.
Discontinue immediately if leucocyte counts exceed 50 x 109/L. Not recommended in myeloid premalignant & malignant condition. Perform WBC count at regular intervals during therapy; CBC is recommended twice wkly during therapy. Monitor bone density in patients w/ underlying osteoporotic bone disease who received Filgrastim. Avoid simultaneous use of Filgrastim w/ chemotherapy & RT. Not recommended in patients w/ severe renal or hepatic function impairment. Pregnancy & lactation. Childn.
Sign Out
